

**AMENDMENTS TO THE SPECIFICATION**

In the first line of the specification, please replace the first sentence with the following:

This is a division of application Serial Number 08/095,640, filed July 21, 1993; now U.S. Patent No. 5,610,279, which is a continuation application of Serial Number 07/580,013, filed September 10, 1990, now abandoned. This application claims priority under 35 U.S.C. § 119 to application Serial Numbers 3319/89, 746/90 and 1347/90, filed on September 12, 1989, March 8, 1990 and April 20, 1990, respectively, all in Switzerland. This application also claims priority under 35 U.S.C. § 119 to European Patent Application Number ~~99100703.0~~ 90116707.2-(now Patent Number EP ~~0939121~~ 0417563), filed August 31, 1990.

Please amend the title to read:

--HUMAN TNF RECEPTOR FUSION PROTEIN--

Please replace the paragraph starting at page 17, line 4 with the following amended paragraph:

--Suitable expression vectors include, for example, vectors such as pBC12MI [ATCC 67 109], pSV2dhfr [ATCC 37 146], pSVL [Pharmacia, Uppsala, Sweden], pRSVcat [ATCC 37 152] and pMSG [Pharmacia, Uppsala, Sweden]. The vectors "pK19" and "pN123" used in Example 9 are especially preferred vectors. These can be isolated according to known methods from E. coli strains HB101(pK19) and HB101(pN123) transformed with them [42]. These E. coli strains have been deposited on the 26th January 1990 at the Deutschen Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) in Braunschweig, FRG, under DSM 5761 for HB101(pK19) and DMS 5764 for HB101(pN123). For the expression of proteins which consist of a soluble fragment of non-soluble TNF-BP and an immunoglobulin fragment, i.e. all domains except the first of the constant region of the heavy chain, there are especially suitable pSV2-derived vectors as described, for example, by German, C. in "DNA Cloning" [Vol. II., ed. by Glover, D. M., IRL Press, Oxford, 1985].

The vectors pCD4-H $\mu$  (DSM 5315, deposited on 21st April 1989), pDC4-H $\gamma$ 1 (DSM 5314, deposited on 21st April 1989) and pCD4-H $\gamma$ 3 (DSM 5523, deposited on 14th September 1989) which have been deposited at the Deutschen Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM) in Braunschweig, FRG, and which are described in detail in European Patent Application No. 90107393.2 are especially preferred vectors. This European Patent Specification and the equivalent Applications referred to in Example 11 also contain data with respect to the further use of these vectors for the expression of chimeric proteins (see also Example 11) and for the construction of vectors for the expression of such chimeric proteins with other immunoglobulin fragments.--